Biotech Values

[cooldrinkh2o]

OSIP: The advantage that Taxotere and Alimta have over Tarceva in this setting is that Medicare will cover the use of Tax and Alimta. Medicare patients w/o drug coverage from a secondary cannot afford to pay for Tarceva. This will change in 2006.

The other advantage that Tax and Alimta have is that oncologists will make a small profit giving those drugs vs. no profit giving Tarceva.

FYI: Did not pick up any stock yesterday as OSIP did not reach $23.50. I have a few underwater options that I picked up earlier, but still will try to get some OSIP at $23 or lower later this month.

PGS, are you a buyer at $18 or are you on the sidelines for this one?